Instil Bio’s hopes for its refreshed clinical pipeline appear to have ended in failure, with...
Instil’s
Instil’s licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US test
A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung...
